Category Archives: Cell Therapy

Coordinates 404215.0N73554.0N Name Pasay City Official name City of Pasay Native name Lungsod ng Pasay Settlement type Highly-Urbanized City Motto Aim High Pasay! Image seal Ph seal ncr pasay.png Seal size 100px Map caption Map of Metro Manila showing the location of Pasay City. Pushpin map Pushpin label position Subdivision type Country Subdivision name Subdivision type1 Region Subdivision name1 National Capital Region Subdivision type2 Province Subdivision name2 none Subdivision type3 Districts Subdivision name3 Lone District of Pasay City Subdivision type4 Barangays Subdivision name4 201 Leader title Mayor Leader name Antonino G. Calixto (Liberal) Leader title1 Vice Mayor Leader name1 Marlon A. Pesebre (Liberal//PMP) Leader title2 Sangguniang Panlungsod Leader name2 Established title2 Incorporated (town) Established date2 December 2, 1863 Established title3 Incorporated (city) Established date3 June 21, 1947 Unit pref Area total km2 19 Population as of 2007 Population total 403,064 Population density km2 21213 Timezone PST Utc offset +8 Elevation footnotes Postal code type ZIP code Postal code 13001309 Area code 2 Website Official Website of Pasay City Footnotes }} The City of Pasay (Filipino: Lungsod ng Pasay) is one of the cities and municipalities that make up Metro Manila in the Philippines. It is bordered on the north by … Continue reading →

Former President and now Pampanga Rep. Gloria Macapagal-Arroyo will undergo stem cell therapy on Monday with an alternative medicine doctor. Arroyo, in a post on her Twitter account Saturday morning, said Monday's session will be her fourth intravenous treatment. "This Monday I will have my fourth stem cell intravenous treatment with my alternative medicine doctor," she said. Also she said, "It's cultured stem cell and much more modest in price than the one coming from sheep or one's own body." But she did not elaborate on how much the treatment will cost. Stem cell therapy is type of intervention strategy that introduces new adult stem cells into damaged tissue in order to treat disease or injury. Earlier this week, Arroyo said she continues to search for alternative solutions to an anatomic problem that prompted her to be rushed to a government hospital last month. Arroyo said she had seen at least two "alternative medicine practitioners," and has initiated communication with a "neurocervical spine purist." She said she also had her thrice-weekly therapy at the Veterans Memorial Medical Center (VMMC) in Quezon City Thursday. Arroyo underwent treatment last August for an anatomic problem that caused her to choke on her food. … Continue reading →

Public release date: 6-Sep-2012 [ | E-mail | Share ] Contact: Sally Stewart Sally.stewart@cshs.org 310-248-6566 Cedars-Sinai Medical Center LOS ANGELES Sept. 6, 2012 A team of Cedars-Sinai Heart Institute stem cell researchers today was awarded a $1.3 million grant from the California Institute of Regenerative Medicine to continue study of an experimental stem cell therapy that treats heart attack patients with heart-derived cells. Earlier this year, data from the first clinical trial of the stem cell treatment showed the therapy helped damaged hearts regrow healthy muscle. To date, this cell therapy, developed by Eduardo Marbn, MD, PhD, director of the Cedars-Sinai Heart Institute and Mark S. Siegel Family Professor, is the only treatment shown to regenerate the injured human heart. In this therapy, human heart tissue is used to grow specialized heart stem cells, which then are injected back into the patient's heart. The new research will focus on understanding the cellular mechanisms that have produced favorable outcomes. "We have seen encouraging results in patients with this treatment, and it has the potential to revolutionize how we treat heart attack patients," Marbn said. "This further study will allow us to better understand how it works, which we hope will lead … Continue reading →

Laking pasasalamat ni Albert Martinez at ng kanyang pamilya na cleared na sa breast cancer ang asawa niyang si Liezl Martinez. Kuwento ni Albert sa PEP.ph (Philippine Entertainment Portal), sa tulong daw ng stem cell therapy ay naging cancer-free ang asawa. Ok naman, so far with Gods blessing,. Its all cleared. So, were very, very happy. Dealing with cancer is a struggle from day one, and Im really thankful that theres such a thing as stem cell na naging solusyon sa recovery ni Liezl." EXTENSIVE RESEARCH. Ayon kay Albert ay pinag-aralan niya ang lahat ng puwedeng maging solusyon sa sakit ng asawa. Pero sa huli, ang stem cell pa rin ang naging solusyon. Marami akong pinagdaanan kasi ni-research ko lahat yan. Kailangang alamin mo kung ano ba ang mga dapat gawin. Lahat pinag-aralan natin And nag-end up talaga, na ang pinakamaganda is stem cell. I took the risk, researched on the possibilities of doing it, availability niya. Link: Albert Martinez claims stem cell therapy cleared wife Liezl Martinez of breast cancer … Continue reading →

NEW YORK, Sept. 5, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NBS) ("NeoStem" or the "Company"), a cell therapy company, today announced that Company management of a NeoStem company, Progenitor Cell Therapy ("PCT"), an internationally recognized contract development and manufacturing organization (CDMO), has been invited to present on its core expertise in development of commercial manufacturing processes for cell therapy at two cell therapy conferences in September. At each, PCT will offer its unique perspective as an industry leader in contract development and manufacturing of cell therapy products, with over 12 years of exclusive cell-therapy focused experience. Timothy Fong, Ph.D, M.B.A, PCT's Vice President, Technology and Product Development, will be sharing PCT's expertise in cell therapy manufacturing with a focus on commercialization. At IBC Life Sciences' Cell Therapy Bioprocessing Conference, he will chair a panel on quality assurance and controls and will give a presentation entitled "From Concept to Product: Considerations for Developing a Robust Commercial Manufacturing Process", which will include considerations for developing a robust commercial manufacturing process. He will also speak at the Stem Cells USA and Regenerative Medicine Congress on "Cell manufacturing considerations for first-in-world stem cell therapeutics". Dr. Fong stated, "As a cell therapeutic progresses from concept … Continue reading →

BURLINGTON, Mass.--(BUSINESS WIRE)-- AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the companys mesenchymal stem cell therapy, as a potential treatment for acute kidney injury (AKI). The randomized, double-blind, placebo-controlled, multi-center trial, designated ACT-AKI (AC607 Trial in Acute Kidney Injury) (NCT01602328), will enroll 200 cardiac surgery subjects at leading tertiary care centers in the United States. ACT-AKI follows the positive results from a phase 1 AC607 trial in cardiac surgery subjects, which showed an excellent safety profile and encouraging data on the incidence of AKI and hospital length of stay, said Robert M. Brenner, M.D., AlloCure President and Chief Executive Officer. We have worked closely with leaders in the field on the design of ACT-AKI, and trial initiation represents an important milestone for AlloCure and the patients we collectively serve. AC607 is a promising therapeutic candidate for AKI, for which effective therapies are greatly needed, said Richard J. Glassock, M.D., Emeritus Professor of Medicine at the Geffen School of Medicine at the University of California, Los Angeles. The initiation of ACT-AKI represents a critical step in the development of an innovative therapy for this all-too-common, serious and costly medical condition, for which no … Continue reading →

NEW YORK, Sept. 4, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a rapidly emerging market leader in the fast growing cell therapy market, today announced that Company management will present at three investor conferences in September. The 19th Annual Newsmakers in the Biotech Industry - BioCentury & Thomson Reuters Rodman & Renshaw Annual Global Investment Conference National Investment Banking Association Conference About NeoStem, Inc. NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT") with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company. Our … Continue reading →

YAHOO: Talent manager Annabelle Rama will fly to Germany in September to undergo therapy - stem cell therapy, that is. This has been a promise made by her son Richard Gutierrez who's footing the bill. "Early this year pa lang ay napagplanuhan na 'yung pagpapa-stem cell ng nanay ko at prinomise ko sa kanya na pag-iipunan ko, prinomise ko sa kanya na ako ang magti-treat sa kanya," Richard said on the first episode of "H.O.T. TV," Aug. 5. He noted, "'Yung mom ko hindi mahilig 'yan na pumunta sa mga doctor, hindi mahilig magpa-check-up." Looking forward This early, Annabelle is already excited about her trip and the upcoming treatment. "Kaya ako excited pumunta kasi unang-una mataas ang aking sugar, mataas ang aking cholesterol, tapos me problema pa ako sa high blood, blood pressure ko. Siguro nga kailangan kong pumunta ng Germany," she said, noting that the condition of her friends, talent manager Lolit Solis and actress Lorna Tolentino, have improved tremendously after going through stem cell therapy. "Nakita ko ang mukha ni Lolis pumuputi ang mukha niya, eh at saka mukha siyang fresh na fresh. Lalo na si LT, nakita ko rin siya. Mukhang gumanda naman siya. Basta lahat ng … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/9fkkzb/cell_therapy_tec) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering. This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice. Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation. Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery … Continue reading →

LEUVEN, BELGIUM--(Marketwire -08/23/12)- TiGenix NV (EURONEXT:TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the half year ending June 30, 2012. Business highlights Financial highlights "The significant progress in all our clinical programs and the commercial ramp up of ChondroCelect in the first half year of 2012 reinforce our position as the European leader in cell therapy," says Eduardo Bravo, CEO of TiGenix. "We continue to consistently deliver on the objectives we set more than a year ago, keeping all key programs on plan, meeting our aggressive targets, and keeping costs under control. In addition, we are in discussions with a number of companies in connection with the US rights to Cx601." Business update Commercial roll-out of ChondroCelect continues to gain momentum ChondroCelect sales for the first half of 2012 amounted to EUR 2.1 million, comprising EUR 1.5 million from 2012 sales, up 115% compared to the same period of last year, and EUR 0.7 million of deferred sales from 2011 as a result of the retroactive reimbursement in the Netherland per January 1, 2011. Discussions to obtain full national reimbursement keep advancing in Spain, France, and Germany. In … Continue reading →